NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
Read More
Tag: Kyprolis
Final NHS green light for Amgen’s Kyprolis
Patients living with multiple myeloma across England and Wales should now get ‘routine’ access to Amgen’s Kyprolis on the NHS within three months following a final green light from the National Institute for Health and Care Excellence.
Read More
Multiple myeloma patients to get NHS access to Amgen’s Kyprolis
The National Institute for Health and Care Excellence is backing routine NHS use of Amgen’s Kyprolis as an option for treating patients with multiple myeloma at first relapse.
Read More
SMC OKs four new therapies for NHS use in Scotland
Cost regulators in Scotland have approved NHS funding for four new medicines, expanding treatment options for lung cancer, iron excess, hepatitis C and chronic pain, but Janssen’s Darzalex was rejected for multiple myeloma.
Read More
NICE rejects earlier use of multiple myeloma drugs
Patients with multiple myeloma are being barred from routine access on the NHS to Celgene’s Revlimid and Amgen’s Kyprolis in the second-line setting.
Read More
NICE rejects NHS funding for multiple myeloma drug Kyprolis
Cost regulators for the NHS in England and Wales are not recommending Amgen’s Kyprolis as a cost-effective use of resources.
Read More
SMC clears three new drugs for NHS Scotland use
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
